Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

HealthDay News — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at ...

GLP-1 RA use is associated with better graft and patient survival among kidney transplant recipients with diabetes.

There is initial evidence that low-dose semaglutide may reduce craving and drinking outcomes in individuals with alcohol-use disorder.

GLP-1 RA use was associated with significantly lower risk of certain cancers compared with metformin use and insulin use.

Unlock the latest advancements in obesity treatment. Expert insights reveal groundbreaking medical breakthroughs and ...

Around 5 million American women have PCOS, which plays into weight, reproductive health, and fertility outcomes. Here's ...

Use of GLP-1 RAs was associated with lower incidence of death-censored graft loss (adjusted subhazard ratio, 0.51) and lower mortality (adjusted hazard ratio, 0.69). GLP-1 RA use was not ...

Because obesity and obesity-related conditions have been linked to several types of cancer, doctors believe that these ...

Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at the annual ...